RCC patients with lower Apelin levels indeed had a significantly longer PFS (median survival = 459.5 days) than patients with higher Apelin levels (median survival = 280 days; Fig 6C and Appendix Fig S3B). This evidence concerns the gene APLN and renal cell adenocarcinoma.